Review demonstrates methods for evaluating mRNA lipid nanoparticles and protein interactions, suggesting pathways to refine targeted intracellular delivery.
The promise of RNA therapeutics is tantalizing to drug delivery scientists, as RNA-encoded genes generally need only reach the cytoplasm to perform their therapeutic functions, circumventing the need for nuclear localization to achieve transcription.1 However, targeted intracellular delivery of mRNA is difficult, requiring precise tuning of carriers to transfect target tissues and cells. The premier mRNA delivery technology is lipid nanoparticles (LNPs), which possess adjuvant properties that make them particularly appealing for mRNA vaccines.
No takes yet. Share an insight, caveat, or question.
Hamilton et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: